NeuroSense Preps for Phase 3 ALS Trial as It Eyes Regulatory Pathway
Event summary
- NeuroSense to present at H.C. Wainwright conference on September 15, 2026, detailing PrimeC's Phase 3 PARAGON trial preparations.
- Management will hold one-on-one investor meetings during the event.
- PrimeC, a novel oral therapy for ALS, targets neuroinflammation, oxidative stress, and iron metabolism.
- Phase 2b PARADIGM study results published in JAMA Neurology showed slowing of functional decline in ALS patients.
- FDA cleared NeuroSense to initiate the pivotal Phase 3 PARAGON trial in ALS.
The big picture
NeuroSense's presentation at the H.C. Wainwright conference comes as the biotech company accelerates its lead drug candidate, PrimeC, toward a pivotal Phase 3 trial for ALS. The strategic focus on multi-target mechanisms and biomarker validation aligns with the growing demand for disease-modifying treatments in neurodegenerative diseases. With the ALS market expected to grow significantly, NeuroSense's ability to navigate regulatory pathways and secure financing will be critical for its long-term success.
What we're watching
- Trial Execution
- How the Phase 3 PARAGON trial design and execution will impact PrimeC's path to regulatory approval.
- Regulatory Strategy
- Whether NeuroSense can secure FDA approval and expand into other key markets.
- Investor Sentiment
- The pace at which investor confidence grows as PrimeC advances through clinical stages.
Related topics